search
Back to results

Dose Finding Study of STR-324

Primary Purpose

Pain, Acute

Status
Unknown status
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Morphine
Morphine HCl
STR-324
Sponsored by
Alaxia SAS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Acute

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Selection criteria:

  1. Patient aged ≥18 to <65 years old, at screening;
  2. Having signed an informed consent prior to any study-related procedure;
  3. Patients planned to undergo a major laparoscopic abdominal or pelvic surgery;
  4. Surgery to be performed without local or regional anaesthesia nor infiltration;
  5. Body mass index (BMI) between 18 and 30 kg/m² inclusive at screening, and with a minimum weight of 50 kg;
  6. Women of childbearing potential must agree to use at least one effective contraceptive method upon enrolment and for 1 cycle following the last dose of the investigational product.

Inclusion Criteria:

The criteria for definitive enrolment must be checked in the Post-Anaesthesia Care Unit (PACU) at the inclusion visit:

  1. NRS-measured pain intensity ranging from 4 to 8 inclusive at baseline PACU measurement;
  2. With a sedation score ≤ S1 (awake or intermittently sleepy) at the time of pain assessment.

Exclusion Criteria:

  1. Patient contra-indicated for morphine administration;
  2. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, major anxiety, or depression). Subjects who take stable doses (same dose >30 days) of antidepressants and/or anti-anxiety drugs may be included;
  3. Women who are pregnant or breastfeeding;
  4. History of alcohol, opiate or other drug abuse.
  5. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator. Minor deviations of values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance;
  6. Clinically significant abnormalities, as judged by the investigator, in laboratory test results;
  7. Participation in an investigational drug or device study within 1 month prior to dosing.

Sites / Locations

  • Leiden University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Standard group

Test group: Infusion with bolus

Test group: Infusion without bolus

Arm Description

Standard treatment (morphine) administered according to usual practice

STR-324 or morphine HCl infusion started with a initial bolus

STR-324 or morphine HCl infusion started without a initial bolus

Outcomes

Primary Outcome Measures

Qualitative Change of Pain Intensity
Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: - Qualitative: a decrease of 2 units minimum from baseline and/or achievement of a pain score ≤ 3 is considered successful, responder=Yes.
Quantitative Change of Pain Intensity
Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: - Quantitative: maximum value of the pain score difference versus baseline.

Secondary Outcome Measures

Adverse events collection
Any untoward medical occurrence in a patient or a clinical investigation subject, which does not necessarily have a causal relationship with the study treatment.

Full Information

First Posted
September 25, 2020
Last Updated
July 8, 2021
Sponsor
Alaxia SAS
search

1. Study Identification

Unique Protocol Identification Number
NCT04582786
Brief Title
Dose Finding Study of STR-324
Official Title
A Proof of Concept Randomized, Double-blind, Parallel Group, Controlled Dose-finding and Safety Study of STR-324 in Post-operative Pain
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
January 2022 (Anticipated)
Study Completion Date
January 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alaxia SAS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to evaluate the analgesic effect and the safety of 4 doses of STR-324 administered as an infusion, with or without initial bolus, to patients suffering from post-operative pain. The sensitivity of the pain model used in the trial will be evaluated with a standard group treated with morphine under the usual care conditions.
Detailed Description
The first step (single-blind standard group) aims to verify the sensitivity of the study pain model in the proposed surgery to confirm the validity of the surgery according to their pain and enrolment rate. 12 patients are planned to be enrolled. The second step (dose-finding study) is a randomized, double-blind, parallel groups, controlled clinical trial involving a total of 106 patients divided into two groups in which patients will be randomized between STR-324 and morphine HCl: Group 1: Titration initiated with a bolus Group 2: Titration without initial bolus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Acute

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Step 1 of the study is single blinded for participants only.
Allocation
Randomized
Enrollment
118 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard group
Arm Type
Active Comparator
Arm Description
Standard treatment (morphine) administered according to usual practice
Arm Title
Test group: Infusion with bolus
Arm Type
Experimental
Arm Description
STR-324 or morphine HCl infusion started with a initial bolus
Arm Title
Test group: Infusion without bolus
Arm Type
Experimental
Arm Description
STR-324 or morphine HCl infusion started without a initial bolus
Intervention Type
Drug
Intervention Name(s)
Morphine
Intervention Description
Repeated bolus according to pain score
Intervention Type
Drug
Intervention Name(s)
Morphine HCl
Intervention Description
Infusion of morphine HCl solution for intravenous administration
Intervention Type
Drug
Intervention Name(s)
STR-324
Intervention Description
Infusion of solution for intravenous administration
Primary Outcome Measure Information:
Title
Qualitative Change of Pain Intensity
Description
Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: - Qualitative: a decrease of 2 units minimum from baseline and/or achievement of a pain score ≤ 3 is considered successful, responder=Yes.
Time Frame
On and/or after study drug, with fixed timepoints at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes. If re-titration is required/performed, additional 5-minutes interval timepoints shall be added.
Title
Quantitative Change of Pain Intensity
Description
Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: - Quantitative: maximum value of the pain score difference versus baseline.
Time Frame
On and/or after study drug, with fixed timepoints at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes. If re-titration is required/performed, additional 5-minutes interval timepoints shall be added.
Secondary Outcome Measure Information:
Title
Adverse events collection
Description
Any untoward medical occurrence in a patient or a clinical investigation subject, which does not necessarily have a causal relationship with the study treatment.
Time Frame
AEs collected directly after surgery until at least 30 days after the day of surgery.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Selection criteria: Patient aged ≥18 to <65 years old, at screening; Having signed an informed consent prior to any study-related procedure; Patients planned to undergo a major laparoscopic abdominal or pelvic surgery; Surgery to be performed without local or regional anaesthesia nor infiltration; Body mass index (BMI) between 18 and 30 kg/m² inclusive at screening, and with a minimum weight of 50 kg; Women of childbearing potential must agree to use at least one effective contraceptive method upon enrolment and for 1 cycle following the last dose of the investigational product. Inclusion Criteria: The criteria for definitive enrolment must be checked in the Post-Anaesthesia Care Unit (PACU) at the inclusion visit: NRS-measured pain intensity ranging from 4 to 8 inclusive at baseline PACU measurement; With a sedation score ≤ S1 (awake or intermittently sleepy) at the time of pain assessment. Exclusion Criteria: Patient contra-indicated for morphine administration; Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, major anxiety, or depression). Subjects who take stable doses (same dose >30 days) of antidepressants and/or anti-anxiety drugs may be included; Women who are pregnant or breastfeeding; History of alcohol, opiate or other drug abuse. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator. Minor deviations of values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance; Clinically significant abnormalities, as judged by the investigator, in laboratory test results; Participation in an investigational drug or device study within 1 month prior to dosing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Annie-Claude Benichou
Phone
+33 4 78 42 95 26
Email
clinical@bioalaxia.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Pascale Vermare
Phone
+33 4 37 53 26 60
Email
clinical@bioalaxia.eu
Facility Information:
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
H05-22
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monique Van Velzen
Phone
+31 71 526 2301
Email
M.van_Velzen@lumc.nl

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Dose Finding Study of STR-324

We'll reach out to this number within 24 hrs